drugset

drugset / Trial / NCT00598650

A Long-term, Extension Study of E2020 in Patients With Dementia With Lewy Bodies

NCT00598650 ↗

Phase 2 Completed 160 enrolled Eisai Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of E2020 in patients with Dementia with Lewy Bodies (DLB).

Timeline

Start: 2008-02
Primary completion: 2011-03
Completion: 2011-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Donepezil	Small molecule	5 mg	Oral

Indications